Orbis Research: Chemotherapy Induced Nausea and Vomiting Market-Pipeline Review, H1 2016

Summary

 

Global Markets Direct’s, ‘Chemotherapy Induced Nausea and Vomiting – Pipeline Review, H1 2016’, provides an overview of the Chemotherapy Induced Nausea and Vomiting pipeline landscape.

 

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects.

 

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/143766

 

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

 

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

 

Scope

– The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting

– The report reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Chemotherapy Induced Nausea and Vomiting therapeutics and enlists all their major and minor projects

– The report assesses Chemotherapy Induced Nausea and Vomiting therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting

 

Purchase a copy of Chemotherapy Induced Nausea and Vomiting-Pipeline Review, H1 2016 visit @ http://www.orbisresearch.com/contact/purchase/143766

 

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting pipeline depth and focus of Indication therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Companies Mentioned:

Ariad Pharmaceuticals, Inc.

AstraZeneca Plc

Bayer AG

Celon Pharma Sp. z o.o.

Pfizer Inc.

Sareum Holdings Plc

Seattle Genetics, Inc.

Teva Pharmaceutical Industries Limited

 

Some Points Form TOC:

 

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Chemotherapy Induced Nausea and Vomiting Overview 9

Therapeutics Development 10

Pipeline Products for Chemotherapy Induced Nausea and Vomiting – Overview 10

Chemotherapy Induced Nausea and Vomiting – Therapeutics under Development by Companies 11

Chemotherapy Induced Nausea and Vomiting – Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Unknown Stage Products 16

Chemotherapy Induced Nausea and Vomiting – Products under Development by Companies 17

Chemotherapy Induced Nausea and Vomiting – Companies Involved in Therapeutics Development 19

Acacia Pharma Limited 19

Aphios Corporation 20

For any enquires before buying, connect with us @ enquiry@orbisresearch.com

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

 

Contact Information:

Hector Costello

Senior Manager – Client Engagements

4144N Central Expressway,

Suite 600, Dallas,

Texas – 75204, U.S.A.

Phone No.: +1 (214) 884-6817; +9164101019

Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research

Follow us on Twitter: https://twitter.com/orbisresearch

Like us on Facebook: https://www.facebook.com/OrbisResearch

Leave a Reply

Designed by CyFocus.com
Powered by CyFocus.net